Targeted Genetics Corporation Strengthens Intellectual Property For AAV Vector Manufacturing Purification Processes

SEATTLE--(BUSINESS WIRE)--Jan. 26, 2006--Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing processes. U.S. patent #6,989,264 is titled, “Methods for generating high titer helper-free preparation of released recombinant AAV vectors.” The patent describes AAV purification processes in which recombinant AAV (rAAV) vectors are highly purified utilizing opposing anion and cation chromatography. This approach leads to highly purified AAV vector stocks and is a more cost-effective and scalable purification approach than can be achieved by centrifugation or single chemistry chromatography. Targeted Genetics’ growing body of intellectual property related to AAV manufacturing supports several of the Company’s product development programs, including its inflammatory arthritis, HIV/AIDS vaccine and congestive heart failure programs.

MORE ON THIS TOPIC